May 24, 2007 by Mike HavrillaA New Era at AEternaA strong balance sheet and a pair of promising products underlie optimism for AEterna's future prospects.
May 23, 2007 by Mike HavrillaCypress Bioscience Comes Full CircleA potential treatment for fibromyalgia sent shares close to $17 today.
May 22, 2007 by Mike HavrillaAvandia Safety Concerns Weigh Down GlaxoA review of clinical studies connects Glaxo's drug with heart trouble.
May 22, 2007 by Mike HavrillaSavient Seems Set for a SuccessWith generic competition against one drug, the company is ready to produce another.
May 22, 2007 by Mike HavrillaColey Gets a Cold ReceptionThe market cares little for this drug developer's promising prospects.
May 22, 2007 by Mike HavrillaAn Emergent OpportunityThe company guided for revenue growth of 10% to 15% for this year.
May 22, 2007 by Mike HavrillaInSite's Vision of ProfitsCould InSite be looking at a surge in its value?
May 21, 2007 by Mike HavrillaAllos Aligned for SuccessWith good news expected ahead, investors might get a relative bargain on Allos now.
May 21, 2007 by Mike HavrillaA New Order at SequenomThe company pushes forward in genetic analysis as it chases large competitors.
May 21, 2007 by Mike HavrillaNovel Developments at NeoseNeose could have positive clinical trial results in the near future.
May 18, 2007 by Mike HavrillaAmple Opportunities for AlnylamThe biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate.
May 17, 2007 by Mike HavrillaPozen Poised for ProfitsIt's a good time to buy shares, because a headache drug could be on its way to the market.
May 17, 2007 by Mike HavrillaJavelin Is Right on TargetThe company reformulates existing drugs to fill unmet needs, making its stock worthy of consideration.
May 17, 2007 by Mike HavrillaPicking Up the Pace at CadenceTwo drugs in testing could find their niche serving hospital patients.
May 16, 2007 by Mike HavrillaBiotech Prospects for a Sizzling SummerConsider these biotech stocks to make your portfolio sizzle this summer.
May 16, 2007 by Mike HavrillaZymoGenetics Is Poised to Stop BleedingWith shares of ZymoGenetics currently trading near three-year lows, now may be a good time to pick some up.
May 16, 2007 by Mike HavrillaWaiting on Memory PharmaceuticalsThe small-cap biotech is testing a treatment for Alzheimer's, but investors should stand by.
May 16, 2007 by Mike HavrillaNastech Nose PotentialSmall biotech with a deep pipeline of promising candidates.
